MedPath

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)

Phase 1
Completed
Conditions
Healthy Adult Subjects
Interventions
Drug: MT-1186
Registration Number
NCT05342597
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Brief Summary

To evaluate the effect of food on the pharmacokinetics of oral edaravone in healthy adult subjects. In this study, we determined 5 different dietary conditions including 4 different meal contents and fasting condition.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
16
Inclusion Criteria

  • Subjects who meet all of the following criteria and who have the capability of giving informed consent will be included in the study.

    1. Healthy adult male or female volunteers
    2. Japanese
    3. Subjects aged between 20 and 45 years at the time of informed consent
    4. Subjects who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study
Read More
Exclusion Criteria

  • Subjects who met any of the following exclusion criteria between screening and investigational product administration were excluded from the study:

    1. Subjects with a current or previous history of cardiac, hepatic, renal, gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine diseases, and those whom the investigator (or subinvestigator) deems unsuitable for the study
    2. History of drug or food allergies
    3. History of alcohol or drug abuse or dependence
    4. Body mass index (BMI) of < 18.0 or > 30.0, or a body weight of < 50 kg [BMI formula: body weight (kg)/height (m)2, rounded to one decimal place]
    5. Positive test for any of the following at screening: hepatitis B surface (HBs) antigen, serological test for syphilis, hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen/antibody
    6. Any clinically significant 12-lead ECG abnormality or corrected QT interval (QTc) using Fridericia's formula (QTcF) interval ≥ 450 msec
    7. Blood donation or sampling with a total volume of ≥ 400 mL within 12 weeks, ≥ 200 mL within 4 weeks, or ≥ 800 mL within one year before providing informed consent
    8. Blood component donation or blood sampling within 2 weeks before providing informed consent
    9. Subjects who have undergone any surgery known to affect the gastrointestinal absorption of drugs (except for appendectomy and herniotomy)
    10. Female subjects who do not agree to use an effective method of contraception from screening or 2 weeks before the start of investigational product administration, whichever comes earlier, to 14 days after the completion (or discontinuation) of investigational product administration. Male subjects who do not agree to use an effective method of contraception from the start of investigational product administration to 14 days after the completion (or discontinuation) of investigational product administration
    11. Subjects who have previously received edaravone
    12. Subjects who have participated in another clinical study and received an investigational product within 12 weeks before providing informed consent
    13. Subjects who have used any drugs other than the single use of acetylsalicylic acid within 7 days before the initiation of investigational product administration
    14. Use of any nutritional supplement(s) within 7 days before the initiation of investigational product administration
    15. Use of alcohol or any products containing xanthin or caffeine within 24 hours before screening and visit on Day -1
    16. Use of grapefruit, grapefruit juice, or any processed food(s) containing these substances within 24 hours before screening and visit on Day -1
    17. Use of any tobacco or nicotine-containing product(s) within 24 hours before screening and visit on Day -1
    18. Female subjects who have a positive pregnancy test at screening and on Day -1, are pregnant or breast feeding, or plan to get pregnant during the study
    19. Subjects judged by the investigator (or subinvestigator) to be unsuitable for the study for any other reason
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Group AMT-1186A single oral dose of MT-1186 with fasted condition in period 1, meal 1 condition in period 2, meal 2 condition in period 3, meal 3 condition in period 4, and meal 4 condition in period 5.
Group BMT-1186A single oral dose of MT-1186 with meal 1 condition in period 1, meal 2 condition in period 2, meal 3 condition in period 3, fasted condition in period 4, and meal 4 condition in period 5.
Group CMT-1186A single oral dose of MT-1186 with meal 2 condition in period 1, meal 3 condition in period 2, fasted condition in period 3, meal 1 condition in period 4, and meal 4 condition in period 5.
Group DMT-1186A single oral dose of MT-1186 with meal 3 condition in period 1, fasted condition in period 2, meal 1 condition in period 3, meal 2 in period 4, and meal 4 condition in period 5.
Primary Outcome Measures
NameTimeMethod
Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide ConjugateBefore administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Mean Residence Time (MRT) of Unchanged EdaravoneBefore administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Renal Clearance (CLr) of Unchanged EdaravoneDay 1 to 9, Day 24 to 26
AUC0-inf of Sulfate Conjugate and Glucuronide ConjugateBefore administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Apparent Distribution Volume at Elimination Phase (Vz/F) of Unchanged EdaravoneBefore administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Apparent Distribution Volume at Steady State (Vss/F) of Unchanged EdaravoneBefore administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Cumulative Urinary Excretion Amount (Ae 0-24h) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide ConjugateDay 1 to 9, Day 24 to 26
Urinary Excretion Ratio (Ae% 0-24h) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide ConjugateDay 1 to 9, Day 24 to 26
Area Under the Concentration Versus Time Curve From Zero up to Infinity (AUC0-inf) of EdaravoneBefore administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Maximum Plasma Concentration (Cmax) of EdaravoneBefore administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Cmax of Sulfate Conjugate and Glucuronide ConjugateBefore administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Terminal Elimination Half-life (t1/2) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide ConjugateBefore administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Apparent Terminal Elimination Rate Constant (Kel) of Unchanged Edaravone, Sulfate Conjugate and Glucuronide ConjugateBefore administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Apparent Total Clearance (CL/F) of Unchanged EdaravoneBefore administration, 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours after administration
Secondary Outcome Measures
NameTimeMethod
Number of Participants With Adverse Events and Adverse Drug ReactionsDay 1 to Day 31

Trial Locations

Locations (1)

Investigational site

🇯🇵

Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy